NEW YORK, NY--(Marketwire - Jul 27, 2012) -  Immunovative, Inc. ("IMUN") (OTCBB: [ IMUN ]) announces today the formation of a Business Advisory Board and the appointment of Bruno Vanderschelden as Chairman. The Business Advisory Board is being formed to provide management with expertise and advice on strategies for raising capital, improving capital structure, and initiate the process to graduate to a senior stock exchange.

The Business Advisory Board of IMUN will complement the plans of our licensor Immunovative Therapies, Ltd. to recruit additional members of its Board of Directors and management team with specific expertise in Biopharmaceutical Drug development, regulatory affairs, clinical trials, manufacturing, distribution and commercialization strategies. 

As Chairman of the Business Advisory Board, Mr. Vanderschelden will assist in recruiting additional business advisor members with broad expertise and experience managing public companies and technical expertise in the biotechnology sector, each bringing unmatched experience and visionary leadership to the table. These exceptional individuals will gather to provide insight to IMUN, act as a sounding board, and share best practices and lessons learned from their respective experience in running and investing in publicly traded companies.

Mr. Vanderschelden has over 15 years of experience in the various fields of asset management and operations in a multi-cultural and multi-lingual environment with longstanding relationships with key industry decision makers, venture investors, and thought leaders, with access to a broad and powerful network of influencers. He has also served as an independent director of various Management Companies, has been instrumental in developing and implementing strategic plans and has implemented risk management and corporate governance programs for public companies. Mr. Vanderschelden has a Masters Degree in Business Administration from ICHEC Brussels, Belgium and a Masters in European Studies from Université Catholique de Louvain Louvain-la-Neuve, Belgium.

"We are very excited about the establishment of our Business Advisory Board and Mr. Vanderschelden's acceptance as its chairman. We have been working with Mr. Vanderschelden for more than a year and have found his input to be invaluable. In addition, he has already contributed securing institutional investment in our current Private Placement," stated Antonio Treminio, Chairman and Chief Executive Officer of Immunovative, Inc.

Mr. Vanderschelden stated: "I am honored that I was selected to join and chair Immunovative's Business Advisory Board. I believe that Immunovative's immunotherapy drugs are on the cutting edge of potentially providing a new method for the treatment of cancer. I am looking forward to utilizing my skill sets to help on the Company's growth and assist in the funding process for future clinical trials."

About Immunovative Inc.:
On December 15, 2011, Immunovative, Inc. ("IMUN") signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products including.

About Immunovative Therapies, Ltd.:
Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israel Office of the Chief Scientist. Immunovative is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. Immunovative Therapies Ltd specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit Immunovative's website at: [ www.immunovative.co.il ]

DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.